Utah Medical Products, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Plans to repurchase at least 800,000 shares at $8 each "if tendered and not withdrawn by shareholders on or before July 9," the firm states. The $8 figure is equal to the highest trading price over the last 12 months. The repurchase plan reflects management's feeling that the stock is currently undervalued relative to the firm's prospects